These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32743869)

  • 21. Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.
    Okam MM; Esrick EB; Mandell E; Campigotto F; Neuberg DS; Ebert BL
    Blood; 2015 Jun; 125(23):3668-9. PubMed ID: 26045597
    [No Abstract]   [Full Text] [Related]  

  • 22. Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia.
    Oldham M; Conrey A; Pittman C; Fisher C; Hargrett S; West K; Jackson M; Martin S; Hsieh MM; Jeffries N; Kaplarevic M; Johnson D; Olkhanud P; Fitzhugh CD
    J Clin Pharmacol; 2021 Jan; 61(1):41-51. PubMed ID: 32673439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are we underestimating the leukemogenic risk of hydroxyurea.
    Al-Jam'a AH; Al-Dabbous IA; Al-Khatti AA; Esan FG
    Saudi Med J; 2002 Nov; 23(11):1411-3. PubMed ID: 12506308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of co-existing α-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids.
    Vasavda N; Woodley C; Allman M; Drašar E; Awogbade M; Howard J; Thein SL
    Br J Haematol; 2012 Apr; 157(2):249-52. PubMed ID: 22082280
    [No Abstract]   [Full Text] [Related]  

  • 25. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
    Altura RA; Wang WC; Wynn L; Altura BM; Altura BT
    J Pediatr; 2002 May; 140(5):565-9. PubMed ID: 12032523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
    Ghafuri DL; Abdullahi SU; Dambatta AH; Galadanci J; Tabari MA; Bello-Manga H; Idris N; Inuwa H; Tijjani A; Suleiman AA; Jibir BW; Gambo S; Gambo AI; Khalifa Y; Haliru L; Abdulrasheed S; Zakari MA; Greene BC; Trevathan E; Jordan LC; Aliyu MH; Baumann AA; DeBaun MR
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e56-e61. PubMed ID: 34001783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
    F1000Res; 2018; 7():. PubMed ID: 30228870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA; Al-Khawlani MM; Al-Akwa A
    Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
    Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
    Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality in sickle cell patients on hydroxyurea therapy.
    Bakanay SM; Dainer E; Clair B; Adekile A; Daitch L; Wells L; Holley L; Smith D; Kutlar A
    Blood; 2005 Jan; 105(2):545-7. PubMed ID: 15454485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea: Analytical techniques and quantitative analysis.
    Marahatta A; Ware RE
    Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol.
    Gwer SO; Onyango KO
    JBI Database System Rev Implement Rep; 2018 May; 16(5):1135-1140. PubMed ID: 29762306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.
    Olnes M; Chi A; Haney C; May R; Minniti C; Taylor J; Kato GJ
    Am J Hematol; 2009 Aug; 84(8):530-32. PubMed ID: 19536844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
    Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Costa E; Tibalinda P; Sterzi E; Leufkens HMG; Makani J; Kaale E; Luzzatto L
    Am J Hematol; 2021 Jan; 96(1):E2-E5. PubMed ID: 32974896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.